Empfehlungen zur antihypertensiven Therapie 
bei Patienten nach Schlaganfall: Zielblutdruck

J. Schrader; S. Lüders; H. Haller; R. Kolloch; E. G. Schulz; P. Trenkwalder; W. Zidek; Schlaganfall-Kommission der Deutschen Hypertonie-Gesellschaft

doi:10.1055/s-0032-1327230

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2012; 137(48): 2511-2514
DOI: 10.1055/s-0032-1327230

Konsensus | Review article

Hypertensiologie

Empfehlungen zur antihypertensiven Therapie bei Patienten nach Schlaganfall: Zielblutdruck

Antihypertensive treatment after stroke: Target blood pressure and treatment recommendations Schlaganfall-Kommission der Deutschen Hypertonie-Gesellschaft ,

J. Schrader

¹St. Josefs-Hospital Cloppenburg

,

S. Lüders

¹St. Josefs-Hospital Cloppenburg

,

H. Haller

²Medizinische Hochschule Hannover

,

R. Kolloch

³Ev. Krankenhaus Gilead Kliniken Bielefeld

,

E. G. Schulz

⁴Nephrologisches Zentrum Göttingen GbR

,

P. Trenkwalder

⁵Klinikum Starnberg

,

W. Zidek

⁶Universitätsklinikum Charité Benjamin Franklin Berlin

› Author Affiliations

Abstract

Schlüsselwörter

Schlaganfall - antihypertensive Therapie - Therapiebeginn-Zielblutdruck

Keywords

Stroke - antihypertensive treatment - initiation of treatment - target blood pressure - antihypertensive drugs

Full Text

References

Literatur
1 Arima H, Chalmers J, Woodward M et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24: 1201-1208
2 Bangalore S, Kumar S, Lobach I et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799-810
3 Beckett NS, Peters R, Fletscher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98
4 Burns JD, Rabinstein AA, Roger VL et al. Incidence and predictors of myocardial infarction after transient ischemic attack: a population-based study. Stroke 2011; 42: 935-940
5 Clement DL, De Buyzere ML, De Bacquer DA et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415
6 Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838
7 Cushman WC, Evans GW, Byington RP et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-95
8 Czernichow S, Zanchetti A, Turnbull F et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to the baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29: 4-16
9 Deutsche Hochdruckliga. Leitlinien-Update 2011-11-22. Deutsche Hochdruckliga e.V. DHL® – Deutsche Hypertonie Gesellschaft: Leitlinien zur Therapie der arteriellen Hypertonie. Heidelberg: 2008
10 Eriksson SE, Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis 2001; 12: 171-80
11 Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6: 1063-1072
12 Jorgensen HS, Nakayama H, Christensen HR et al. Blood Pressure in Acute Stroke. Cerebrovasc Dis 2002; 13: 204-209
13 Kai H, Ueno T, Kimura T et al. Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. J Hypertension 2011; 29: 1889-1896
14 Kim Y-S, Davis S, Truijen J et al. Intensive blood-pressure control affects cerebral blood flow in in type 2 diabetes mellitus patients. Hypertension 2011; 57: 738-745
15 Lindholm LH, Carlberg B, Samuelssson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366; 1545-53
16 Lovibond K, Jowett S, Barton P et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011; 378: 1219-1230
17 MacMahon S, Rodgers A. Primary and secondary prevention of stroke. Clin Exp Hypertens 1996; 18: 537-46
18 Messerli FH, Mancia G, Conti R et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Int Med 2006; 144: 884-893
19 O`Donell MJ, Xavier D, Liu L et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 Countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376: 112-123
20 Ovbiagele B, Diener HC, Yusuf S et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306: 2137-2144
21 PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041
22 Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used first line agents: a network meta-analysis. JAMA 2003; 289: 2534-44
23 Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741-2749
24 Reboldi G, Gentile G, Angeli F et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens 2011; 29: 1253-1269
25 Sandset EC, Bath PM, Boysen G. SCAST Study Group et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377: 741-750
26 Schrader J, Lüders S, Kulschewski A et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703
27 Schrader J, Lüders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226
28 Schrader J. Blutdrucksenkung nach Schlaganfall. Dtsch Med Wochenschr 2006; 131: 758-761
29 Schrader J, Lüders S. Prävention des Schlaganfalls durch Blutdrucksenkung. Dtsch Med Wochenschr 2011; 136: 2045-2049
30 Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369
31 Tu JV. Reducing the global burden of stroke. Lancet 2010; 376: 74-75
32 Turnball F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35
33 Yusuf S, Diener HC, Sacco RL. PRoFESS Study Group et al. Telmisartan toprevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-37
34 Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertension 2009; 27: 923-934